NIFTY 50 23344.75 ▲ (0.61%)
NIFTY NEXT 50 65106.15 ▲ (0.08%)
NIFTY 100 24048.8 ▲ (0.51%)
NIFTY MIDCAP 100 55106.2 ▲ (0.91%)
NIFTY SMALLCAP 100 17864.65 ▲ (1.09%)
NIFTY SMALLCAP 250 16841.4 ▲ (0.84%)
NIFTY MIDCAP SELECT 12356.5 ▲ (0.87%)
NIFTY TOTAL MARKET 12304.6 ▲ (0.6%)
NIFTY BANK 49350.8 ▲ (1.67%)
SENSEX 77073.44 ▲ (0.59%)
BSE BANKEX 56036.23 ▲ (2.03%)

Lincoln Pharmaceuticals : Q4 2024 Financial Quarterly Report : YoY Sales Up 26.71 %, QoQ Down 2.7 %

May 18, 2024May 18, 2024| adminadmin| 0 Comments| 1:35 pm
Image is loading
Categories:

Share the post "Lincoln Pharmaceuticals : Q4 2024 Financial Quarterly Report : YoY Sales Up 26.71 %, QoQ Down 2.7 %"

  • Facebook
  • LinkedIn
  • X
  • Tumblr
  • WhatsApp
  • TelegramTelegram
  • Email

Highlights

  • Sales over the Year and quarter: The company experienced a substantial growth of 26.71 % in the past year, decrease in net sales/revenue by -2.7 %.
  • Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 80 %. Marginal decrease of -36.3% in other income during this quarter.
  • Profit over the Year and quarter: Significant improvement in profitability for Lincoln Pharmaceuticals ltd.. Notable increase of 48.04 % in net profit Year to Year, Lincoln Pharmaceuticals ltd.’s profitability dropped by -33.68 % Quarter to Quarter.
  • EPS over the Year and quarter: EPS increased by 48.01 % Year to Year. EPS decreased by -33.71 % in previous quarter. Analysis needed for shareholder value.

The comprehensive analytics outlining the performance and outlook of Lincoln Pharmaceuticals ltd.”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 112.46 Cr Rs. 146.449 Cr Rs. 142.493 Cr -2.7 % + 26.71 %
Expenses Rs. 95.82 Cr Rs. 116.78 Cr Rs. 124.11 Cr + 6.28 % + 29.52 %
Operating Profit Rs. 16.64 Cr Rs. 29.67 Cr Rs. 18.38 Cr -38.05 % + 10.46 %
OPM % 14.8 % 20.26 % 12.9 % -7.36 % -1.9 %
Other Income Rs. 3.9 Cr Rs. 11.02 Cr Rs. 7.02 Cr -36.3 % + 80 %
Interest Rs. 1.15 Cr Rs. 0.16 Cr Rs. 0.5 Cr + 212.5 % -56.52 %
Depreciation Rs. 2.41 Cr Rs. 2.81 Cr Rs. 2.69 Cr -4.27 % + 11.62 %
Profit before tax Rs. 16.98 Cr Rs. 37.72 Cr Rs. 22.21 Cr -41.12 % + 30.8 %
Tax % 26.01 % 25.64 % 16.29 % -9.35 % -9.72 %
Net Profit Rs. 12.56 Cr Rs. 28.04 Cr Rs. 18.6 Cr -33.67 % + 48.09 %
EPS in Rs Rs. 6.27 Rs. 14 Rs. 9.28 -33.71 % + 48.01 %


Today, we’re looking at Lincoln Pharmaceuticals ltd.’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 26.71 %. However, it did see a marginal slip of -2.7 % from the previous quarter. Expenses ticked up slightly by 6.28 % quarter-on-quarter, aligning with the annual rise of 29.52 %. Operating profit, while up 10.46 % compared to last year, faced a quarter-on-quarter dip of -38.05 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -1.9 %, but a shrinkage of -7.36 % sequentially. Other income fell by -36.3 % compared to the last quarter, despite an annual growth of 80 %. Interest expenses surged remarkably by 212.5 % from the previous quarter, yet the year-over-year decrease remains at a moderate -56.52 %. Depreciation costs fell by -4.27 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 11.62 %. Profit before tax grew annually by 30.8 % but saw a reduction from the preceding quarter by -41.12 %.
Tax expenses as a percentage of profits decreased slightly by -9.72 % compared to last year, with a more notable quarter-on-quarter decrease of -9.35 %. Net profit rose by 48.09 % year-on-year but witnessed a -33.67 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 48.01 % but a quarterly fall of -33.71 %. In summary, Lincoln Pharmaceuticals ltd.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 112.46 Cr Rs. 146.449 Cr Rs. 142.493 Cr -2.7 % + 26.71 %
Expenses Rs. 95.82 Cr Rs. 116.78 Cr Rs. 124.11 Cr + 6.28 % + 29.52 %
Operating Profit Rs. 16.64 Cr Rs. 29.67 Cr Rs. 18.38 Cr -38.05 % + 10.46 %
Net Profit Rs. 12.56 Cr Rs. 28.04 Cr Rs. 18.6 Cr -33.67 % + 48.09 %
EPS in Rs Rs. 6.27 Rs. 14 Rs. 9.28 -33.71 % + 48.01 %


In reviewing Lincoln Pharmaceuticals ltd.’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 26.71 % year-on-year growth, although there was a slight dip of -2.7 % from the previous quarter. Expenses rose by 29.52 % compared to the previous year, with a 6.28 % increase quarter-on-quarter. Operating Profit surged by 10.46 % annually, and saw a -38.05 % decrease from the last quarter.
Net Profit showed yearly increase of 48.09 %, and experienced a -33.67 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 48.01 % annually, however dipped by -33.71 % compared to the last quarter. In essence, while Lincoln Pharmaceuticals ltd. exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.

[my_shortcode1 values=”Lincoln Pharmaceuticals “]

Related Post